Monitoring Agency Report for the quarter ended March 31, 2026- in relation to the Rights Issue of the Company.

Rights For Debt RepaymentFund Raising View source PDF

HCG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+2.2%1-day move

₹605.20

prior close

₹613.35

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.0-0.1+0.3+2.2+5.2+4.8+7.3+7.4+8.3+5.6+3.8+12.3—

Up moveDown movePending

AI summary

Healthcare Global Enterprises (HCG) has filed its first Monitoring Agency Report for a Rs. 424.68 crore Rights Issue that ran from March 11-25, 2026. CARE Ratings Limited, the monitoring agency, confirms zero utilization during Q4FY26 with the entire proceeds sitting idle in Axis Bank accounts. The planned deployment includes Rs. 170 crore for debt repayment, Rs. 154.04 crore for acquiring an additional 34% stake in Vizag Hospital and Cancer Research Center, Rs. 95.57 crore for general corporate purposes, and Rs. 5.07 crore for issue expenses. No deviations from the stated objects were observed.

Likely market impact

The nil utilization means the company has not yet deployed capital toward debt reduction or the Vizag acquisition, which could delay deleveraging benefits. Shareholders should expect deployment in upcoming quarters as the company executes its stated objectives.